Patent · US Active

Chimeric antigen receptor-modified immune effector cell carrying PD-L1 blocking agent

US11299525B2 · kind B2 · utility

0Cited by

0References

11Claims

0Family size

Assignee

CRAGE MEDICAL CO., LIMITED · CN

Inventors

Zonghai LI · Shanghai, CN
Zeyan Pan · Shanghai, CN
Zhimin Shi · Bellevue, US
Bo Song · Princeton, US
Peng Wang · Carlsbad, US

Key dates

Filing date	Oct 31, 2016
Grant date	Apr 12, 2022
Priority date	—
Expiry date	Mar 12, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N15/63
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided is a chimeric antigen receptor-modified immune effector cell carrying a procedural death ligand 1 (PD-L1) blocking agent. Also provided is a method for secreting and expressing a PD-L1 blocking agent using the immune effector cell as a carrier to improve the anti-tumour effect of the chimeric antigen receptor-modified immune effector cell.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.